查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829931

2025年全球乳癌液態切片市場報告

Breast Cancer Liquid Biopsy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，乳癌液態切片市場規模迅速擴張，從2024年的7.8億美元成長到2025年的8.9億美元，複合年成長率為14.2%。預測期內的成長歸因於次世代定序(NGS) 的進步、乳癌盛行率的上升、對非侵入性診斷的需求不斷成長、個人化醫療的普及以及癌症研究資金的增加。

預計未來幾年乳癌液態切片市場將快速成長，到2029年將達到15.3億美元，複合年成長率為14.5%。預測期內的成長動力包括：液態切片檢測技術的進步、液態切片在早期癌症篩檢中的應用日益廣泛、對即時癌症監測的需求不斷成長、精準腫瘤學應用的不斷擴展以及對液態切片研發投入的不斷增加。預測期內的主要趨勢包括：人工智慧在液態切片分析中的整合、單細胞測序的進步、多體學液態切片平台的開發、液態切片靈敏度和特異性的提高，以及數位PCR在超精準突變檢測中的應用。

乳癌液態切片是一種微創測試，可檢測和分析患者血液和其他體液中的腫瘤衍生質能，無需進行傳統的切片檢查即可提供乳癌的存在、進展和遺傳特徵的寶貴見解。

乳癌液態切片的主要產品包括耗材和套件。耗材是指用於檢測和分析乳癌相關生物標記的液態切片試驗的一次性材料、試劑和試劑套件。關鍵生物標記包括細胞外囊泡（EV）、遊離DNA（cfDNA）、循環腫瘤RNA（ctRNA）、循環性腫瘤細胞（CTC）和遊離RNA（cfRNA）。這些生物標記用於早期檢測、篩檢和診斷。乳癌液態切片的最終用戶包括研究實驗室、醫院、醫生實驗室、參考實驗室、公共衛生實驗室、研究機構、小分子實驗室和病理實驗室。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要醫療設備重新認證，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供乳癌液態切片市場統計數據，包括全球市場規模、各地區市場佔有率、乳癌液態切片市場佔有率的競爭對手、詳細的乳癌液態切片細分市場、市場趨勢和商機，以及您在乳癌液態切片行業取得成功所需的乳癌。本乳癌液態切片液態切片研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

未來五年的預測成長率為14.5%，較我們先前對該市場的預測略有下降0.2%。下降的主要原因是美國與其他國家之間的關稅影響。這項影響將直接影響美國，導致來自美國和丹麥等主要地區的循環腫瘤去氧核糖核酸(DNA) 分離套件和次世代定序的供應鏈中斷，從而可能增加微創癌症檢測的成本。

預計未來幾年乳癌患者數量的增加將推動乳癌液態切片市場的成長。乳癌是一種在乳腺細胞中發展的惡性腫瘤，通常發生在產乳小葉或將乳汁輸送到乳頭的乳管中。乳癌發生率的上升歸因於遺傳易感性、荷爾蒙失調、老化、生活方式改變、肥胖、飲酒、缺乏運動、輻射暴露和環境污染物等因素。乳癌液態切片透過檢測血液中的循環腫瘤 DNA (ctDNA) 或循環性腫瘤細胞(CTC) 來發揮治療作用，從而實現即時疾病監測。這有助於評估治療效果、檢測治療抗藥性並識別標靶治療的基因突變。例如，根據致力於癌症研究、教育、宣傳和患者支持的美國非營利組織美國癌症協會的數據，預計乳癌新患者病例數將從 2024 年的 313,510 例增加到 2025 年的 319,750 例。因此，乳癌發生率的上升正在刺激乳癌液態切片市場的擴張。

乳癌液態切片市場的主要企業正專注於伴隨診斷等創新市場發展，透過識別最能從特定治療方法中獲益的患者來促進個人化護理。伴隨診斷利用液態切片技術檢測生物標記物，例如基因突變、循環腫瘤 DNA (ctDNA) 和指示治療反應的蛋白質表現。例如，2023 年 1 月，美國生物技術公司 Guardant Health Inc. 的 Guardant360 CDx液態切片測試獲得美國食品藥物管理局(FDA)核准，可作為美納里尼集團 ORSERDU (elacestrant) 的伴隨診斷，該藥物用於治療攜帶 ESR1 基因突變的進行性或轉移性乳癌患者。此項核准使腫瘤學家能夠使用該測試進行全面的基因組分析，並識別可能受益於標靶治療的患者。此項核准標誌著 Guardant Health 首次獲得 FDA核准用於乳癌，並增強了該公司在精準腫瘤學領域的地位。

2024年1月，Guardant Health將與Hikma Pharmaceuticals合作，利用Guardant Health先進的液態切片和組織活體組織切片技術進行早期癌症檢測、復發監測和最佳化治療方案。此次合作將增強Guardant Health的全球影響力，並緩解中東和北非地區日益成長的癌症負擔。 Hikma Pharmaceuticals是一家總部位於英國的製藥公司，專注於創新醫療解決方案。

乳癌液態切片市場由提供早期癌症檢測、治療監測、微量殘存疾病(MRD) 檢測、復發預測和用於標靶治療選擇的基因突變分析等服務的營業單位所獲得的收益組成。市場價值還包括服務提供者銷售或包含在其服務產品中的相關產品的價值。乳癌液態切片市場還包括循環腫瘤 DNA (ctDNA) 檢測試劑套件、循環性腫瘤細胞(CTC) 檢測系統、次世代定序儀(NGS) 試劑盒、基於 PCR 的液態切片測試、採血管以及用於非侵入性癌症診斷和監測的消耗品和試劑的銷售。此市場的價值代表“出廠價”，即產品製造商或創造者向其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接向最終客戶銷售的產品價值。該市場中的產品價值還包括產品創造者銷售的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球乳癌液態切片：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球乳癌液態切片市場：成長率分析
  • 全球乳癌液態切片市場表現：規模與成長，2019-2024
  • 全球乳癌液態切片市場預測：規模與成長，2024-2029，2034
  • 全球乳癌液態切片：總目標市場（TAM）

第6章 市場細分

  • 全球乳癌液態切片市場（依產品、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 耗材
  • 套件
  • 全球乳癌液態切片市場（依生物標記、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 細胞外囊泡（EV）
  • 遊離DNA（cfDNA）
  • 循環腫瘤RNA（ctRNA）
  • 循環性腫瘤細胞（CTC）
  • 遊離RNA
  • 其他生物標記
  • 全球乳癌液態切片市場的應用、表現及預測（2019-2024、2024-2029、2034）
  • 早期檢測或篩檢
  • 診斷
  • 其他用途
  • 全球乳癌液態切片市場（按最終用戶、業績和預測），2019-2024 年、2024-2029 年、2034 年
  • 研究所
  • 醫院
  • 醫生檢查室
  • 參考實驗室
  • 公共衛生研究所
  • 研究所
  • 小分子研究所
  • 病理實驗室
  • 全球乳癌液態切片市場：按耗材（類型）細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 試劑
  • 聚合酵素鏈鎖反應（PCR）檢測
  • 序列面板
  • 樣本收集管
  • 全球乳癌液態切片市場：按試劑套件類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 基於DNA的液態生物檢體套件
  • 基於RNA的液態生物檢體套件
  • 多標記液態生物檢體套件

第7章 區域和國家分析

  • 全球乳癌液態切片市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球乳癌液態切片市場：國家、績效及預測（2019-2024、2024-2029、2034）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 乳癌液態切片市場：競爭格局
  • 乳癌液態切片市場：公司簡介
    • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Agilent Technologies Inc.
  • Illumina Inc.
  • Sysmex Corporation
  • Qiagen NV
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories
  • Guardant Health Inc.
  • Twist Bioscience
  • Foundation Medicine Inc.
  • Biodesix Inc.
  • Menarini Silicon Biosystems
  • Datar Cancer Genetics
  • Abcam plc
  • OncoDNA SA
  • Genomic Health Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年乳癌液態切片市場：哪些國家將提供新機會
  • 2029年乳癌液態切片市場：細分領域帶來新機會
  • 2029年乳癌液態切片市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r33985u

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient's blood or other bodily fluids, offering valuable insights into the presence, progression, and genetic profile of breast cancer without the need for a traditional tissue biopsy.

The primary products used in breast cancer liquid biopsy include consumables and kits. Consumables refer to disposable materials, reagents, and kits utilized in liquid biopsy tests to detect and analyze biomarkers associated with breast cancer. The key biomarkers include extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), and others. These biomarkers are applied in early detection or screening, diagnosis, and other purposes. The end users of breast cancer liquid biopsy encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The breast cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides breast cancer liquid biopsy market statistics, including breast cancer liquid biopsy industry global market size, regional shares, competitors with a breast cancer liquid biopsy market share, detailed breast cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer liquid biopsy industry. This breast cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.78 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to advancements in next-generation sequencing (ngs), increasing prevalence of breast cancer, growing demand for non-invasive diagnostic methods, rising adoption of personalized medicine, and increased funding for cancer research.

The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to technological advancements in liquid biopsy assays, increasing adoption of liquid biopsy in early cancer screening, rising demand for real-time cancer monitoring, expanding applications in precision oncology, growing investments in liquid biopsy research and development. Major trends in the forecast period include integration of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing, development of multi-omics liquid biopsy platforms, improvement in liquid biopsy sensitivity and specificity, and adoption of digital pcr for ultra-precise mutation detection.

The forecast of 14.5% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for circulating tumor deoxyribonucleic acid (DNA) isolation kits and next-generation sequencing reagents, sourced from key regions such as China and Denmark, which could lead to increased costs for minimally invasive cancer detection.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising number of breast cancer cases is expected to drive the growth of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that originates in the breast cells, typically in the milk-producing lobules or the ducts that transport milk to the nipple. The increasing prevalence of breast cancer is attributed to factors such as genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy plays a crucial role in treatment by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. It helps assess treatment response, detect therapy resistance, and identify genetic mutations for targeted therapies. For example, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, new breast cancer cases are projected to increase from 313,510 in 2024 to 319,750 in 2025. As a result, the growing incidence of breast cancer is fueling the expansion of the breast cancer liquid biopsy market.

Leading companies in the breast cancer liquid biopsy market are focusing on innovative developments, such as companion diagnostics, to facilitate personalized treatment by identifying patients who are most likely to benefit from specific therapies. Companion diagnostics leverage liquid biopsy technology to detect biomarkers, including genetic mutations, circulating tumor DNA (ctDNA), and protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to conduct comprehensive genomic profiling using the test, enabling them to identify patients who may benefit from targeted therapy. It also marks Guardant Health's first FDA approval for breast cancer, strengthening its presence in precision oncology.

In January 2024, Guardant Health Inc. partnered with Hikma Pharmaceuticals plc to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health's advanced liquid and tissue biopsy technologies. This collaboration strengthens Guardant Health's global presence and addresses the increasing cancer burden in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company specializing in innovative healthcare solutions.

Major players in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc.

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the breast cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Consumables; Kits
  • 2) By Biomarkers: Extracellular Vesicles (EVs); Cell-free DNA (cfDNA); Circulating Tumor RNA (ctRNA); Circulating Tumor Cells (CTCs); Cell-free RNA (cfRNA); Other Biomarkers
  • 3) By Application: Early Detection Or Screening; Diagnosis; Other Applications
  • 4) By End Users: Laboratories; Hospitals; Physician Laboratories; Reference Laboratories; Public Health Laboratories; Research Institutes; Small Molecular Laboratories; Pathology Laboratories
  • Subsegments:
  • 1) By Consumables: Reagents; Polymerase Chain Reaction (PCR) Assays; Sequencing Panels; Sample Collection Tubes
  • 2) By Kits: DNA-based Liquid Biopsy Kits; RNA-based Liquid Biopsy Kits; Multi-marker Liquid Biopsy Kits
  • Companies Mentioned: Johnson & Johnson Private Limited; Roche Diagnostics; Merck KGaA; Thermo Fisher Scientific; Siemens Healthineers; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Qiagen N.V.; Myriad Genetics Inc.; NeoGenomics Laboratories; Guardant Health Inc.; Twist Bioscience; Foundation Medicine Inc.; Biodesix Inc.; Menarini Silicon Biosystems; Datar Cancer Genetics; Abcam plc; OncoDNA SA; Genomic Health Inc.; RainDance Technologies; Biocept Inc.; Fluxion Biosciences Inc.; Angle plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Liquid Biopsy Market Characteristics

3. Breast Cancer Liquid Biopsy Market Trends And Strategies

4. Breast Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Breast Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Breast Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Breast Cancer Liquid Biopsy Market Growth Rate Analysis
  • 5.4. Global Breast Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Breast Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Breast Cancer Liquid Biopsy Total Addressable Market (TAM)

6. Breast Cancer Liquid Biopsy Market Segmentation

  • 6.1. Global Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Consumables
  • Kits
  • 6.2. Global Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Extracellular Vesicles (EVs)
  • Cell-free DNA (cfDNA)
  • Circulating Tumor RNA (ctRNA)
  • Circulating Tumor Cells (CTCs)
  • Cell-free RNA (cfRNA)
  • Other Biomarkers
  • 6.3. Global Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Early Detection Or Screening
  • Diagnosis
  • Other Applications
  • 6.4. Global Breast Cancer Liquid Biopsy Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratories
  • Hospitals
  • Physician Laboratories
  • Reference Laboratories
  • Public Health Laboratories
  • Research Institutes
  • Small Molecular Laboratories
  • Pathology Laboratories
  • 6.5. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents
  • Polymerase Chain Reaction (PCR) Assays
  • Sequencing Panels
  • Sample Collection Tubes
  • 6.6. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-based Liquid Biopsy Kits
  • RNA-based Liquid Biopsy Kits
  • Multi-marker Liquid Biopsy Kits

7. Breast Cancer Liquid Biopsy Market Regional And Country Analysis

  • 7.1. Global Breast Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Breast Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Liquid Biopsy Market

  • 8.1. Asia-Pacific Breast Cancer Liquid Biopsy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Liquid Biopsy Market

  • 9.1. China Breast Cancer Liquid Biopsy Market Overview
  • 9.2. China Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Liquid Biopsy Market

  • 10.1. India Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Liquid Biopsy Market

  • 11.1. Japan Breast Cancer Liquid Biopsy Market Overview
  • 11.2. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Liquid Biopsy Market

  • 12.1. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Liquid Biopsy Market

  • 13.1. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Liquid Biopsy Market

  • 14.1. South Korea Breast Cancer Liquid Biopsy Market Overview
  • 14.2. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Liquid Biopsy Market

  • 15.1. Western Europe Breast Cancer Liquid Biopsy Market Overview
  • 15.2. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Liquid Biopsy Market

  • 16.1. UK Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Liquid Biopsy Market

  • 17.1. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Liquid Biopsy Market

  • 18.1. France Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Liquid Biopsy Market

  • 19.1. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Liquid Biopsy Market

  • 20.1. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Liquid Biopsy Market

  • 21.1. Eastern Europe Breast Cancer Liquid Biopsy Market Overview
  • 21.2. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Liquid Biopsy Market

  • 22.1. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Liquid Biopsy Market

  • 23.1. North America Breast Cancer Liquid Biopsy Market Overview
  • 23.2. North America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Liquid Biopsy Market

  • 24.1. USA Breast Cancer Liquid Biopsy Market Overview
  • 24.2. USA Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Liquid Biopsy Market

  • 25.1. Canada Breast Cancer Liquid Biopsy Market Overview
  • 25.2. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Liquid Biopsy Market

  • 26.1. South America Breast Cancer Liquid Biopsy Market Overview
  • 26.2. South America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Liquid Biopsy Market

  • 27.1. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Liquid Biopsy Market

  • 28.1. Middle East Breast Cancer Liquid Biopsy Market Overview
  • 28.2. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Liquid Biopsy Market

  • 29.1. Africa Breast Cancer Liquid Biopsy Market Overview
  • 29.2. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

  • 30.1. Breast Cancer Liquid Biopsy Market Competitive Landscape
  • 30.2. Breast Cancer Liquid Biopsy Market Company Profiles
    • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Liquid Biopsy Market Other Major And Innovative Companies

  • 31.1. Agilent Technologies Inc.
  • 31.2. Illumina Inc.
  • 31.3. Sysmex Corporation
  • 31.4. Qiagen N.V.
  • 31.5. Myriad Genetics Inc.
  • 31.6. NeoGenomics Laboratories
  • 31.7. Guardant Health Inc.
  • 31.8. Twist Bioscience
  • 31.9. Foundation Medicine Inc.
  • 31.10. Biodesix Inc.
  • 31.11. Menarini Silicon Biosystems
  • 31.12. Datar Cancer Genetics
  • 31.13. Abcam plc
  • 31.14. OncoDNA SA
  • 31.15. Genomic Health Inc.

32. Global Breast Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market

34. Recent Developments In The Breast Cancer Liquid Biopsy Market

35. Breast Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

  • 35.1 Breast Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Breast Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Breast Cancer Liquid Biopsy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer